<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03720704</url>
  </required_header>
  <id_info>
    <org_study_id>VBX 17-04</org_study_id>
    <nct_id>NCT03720704</nct_id>
  </id_info>
  <brief_title>Post-Market Registry of the GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis Implanted in Peripheral Vessels</brief_title>
  <acronym>EXPAND</acronym>
  <official_title>Post-Market Registry of the GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis Implanted in Peripheral Vessels</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>W.L.Gore &amp; Associates</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>W.L.Gore &amp; Associates</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the VBX 17-04 registry is to collect post-market safety and&#xD;
      performance data of the GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis (VBX Stent&#xD;
      Graft) in peripheral vessels in patients who require interventional treatment&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 18, 2018</start_date>
  <completion_date type="Anticipated">March 2026</completion_date>
  <primary_completion_date type="Anticipated">November 2021</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>5 Years</target_duration>
  <primary_outcome>
    <measure>Composite of Procedural Success and freedom from VBX Stent Graft-related Serious Adverse Events</measure>
    <time_frame>30 days post treatment</time_frame>
    <description>Number of study subjects experiencing Procedural Success and free from VBX Stent Graft-related Serious Adverse Events within 30 days of index procedure.&#xD;
Procedural Success is defined as: successful access, delivery, accurate deployment, and withdrawal of catheters with patent VBX Stent Graft at end of procedure.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">280</enrollment>
  <condition>Peripheral Vascular Diseases</condition>
  <arm_group>
    <arm_group_label>GORE VIABAHN VBX Balloon Expandable Endoprosthesis</arm_group_label>
    <description>The GORE VIABAHN VBX Balloon Expandable Endoprosthesis will be implanted according to the institution standard of practice in patients needing preservation of peripheral vessels due to multiple pathologies and conditions.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>GORE VIABAHN VBX Balloon Expandable Endoprosthesis</intervention_name>
    <description>GORE VIABAHN VBX Balloon Expandable Endoprosthesis will be implanted in peripheral vessels in patients who require interventional treatment.</description>
    <arm_group_label>GORE VIABAHN VBX Balloon Expandable Endoprosthesis</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The registry has been designed with broad eligibility criteria to capture real-world VBX&#xD;
        Stent Graft use, in multiple pathologies and in conditions needing preservation of&#xD;
        peripheral vessels.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥ 18 years.&#xD;
&#xD;
          -  Signed informed consent form&#xD;
&#xD;
          -  Endovascular indication for treatment based on treating physician's best medical&#xD;
             judgment.&#xD;
&#xD;
          -  Intend for no other stents to be placed in the same peripheral vessel(s) targeted for&#xD;
             VBX Stent Graft placement.&#xD;
&#xD;
          -  Willingness of the patient to adhere to standard of care follow-up requirements.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known hypersensitivity to heparin or a previous incident of Heparin-Induced&#xD;
             Thrombocytopenia (HIT) type II.&#xD;
&#xD;
          -  Participation in concurrent research study or registry which may confound registry&#xD;
             results, unless approved by Gore.&#xD;
&#xD;
          -  Pregnant or breast-feeding female at time of informed consent signature.&#xD;
&#xD;
          -  Life expectancy &lt; 12 months due to comorbidities.&#xD;
&#xD;
          -  Use of the VBX Stent Graft is for the treatment of de novo iliac occlusive disease.&#xD;
&#xD;
          -  Use of the VBX Stent Graft is for the treatment of aortic coarctations.&#xD;
&#xD;
          -  Use of the VBX Stent Graft in the coronary, pulmonary, carotid, vertebral, isolated&#xD;
             infrarenal aortic, or vena cava vessels.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mauro Gargiulo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Azienda Ospedaliera Policlinico Sant'Orsola Malpighi</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Suzy Palmer</last_name>
    <phone>00-1-928-864-3670</phone>
    <email>supalmer@wlgore.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Cinzia Santin</last_name>
    <phone>39/3463645539</phone>
    <email>csantin@wlgore.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hôpital Marie Lannelongue</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephan Haulon, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dittmar Bӧckler, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. Franziskus Hospital</name>
      <address>
        <city>Münster</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin J Austermann, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Policlinico Sant'Orsola Malpighi</name>
      <address>
        <city>Bologna</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mauro Gargiulo, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fondazione Poliambulanza</name>
      <address>
        <city>Brescia</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Raffaello Bellosta, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero-Universitaria di Padova</name>
      <address>
        <city>Padova</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Michele Antonello, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale di Circolo e Fondazione Macchi</name>
      <address>
        <city>Varese</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gabriele Piffaretti, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Medical Center Groningen</name>
      <address>
        <city>Groningen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ignace Tielliu, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Erasmus Medical Center</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hence Verhagen, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Central de Asturias (HUCA)</name>
      <address>
        <city>Oviedo</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Manuel Alonso Perez, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital of Santiago de Compostela</name>
      <address>
        <city>Santiago De Compostela</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jorge Fernandez Noya, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>September 14, 2018</study_first_submitted>
  <study_first_submitted_qc>October 24, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 25, 2018</study_first_posted>
  <last_update_submitted>May 24, 2021</last_update_submitted>
  <last_update_submitted_qc>May 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Lesion-exclusion</keyword>
  <keyword>Visceral Perfusion</keyword>
  <keyword>Luminal Reconstruction</keyword>
  <keyword>Occlusive Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vascular Diseases</mesh_term>
    <mesh_term>Peripheral Vascular Diseases</mesh_term>
    <mesh_term>Peripheral Arterial Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

